NUS PTP1B Cancer Immunotherapy Breakthrough | JACS Study
NUS researchers uncover PTP1B as key target enhancing immunogenic cell death in cancer immunotherapy, per landmark JACS study. Explore implications for Singapore's oncology future.
No reviews yet. Be the first to rate Wee Han!
Professor Wee Han Ang is a Professor of Chemistry at the National University of Singapore (NUS). He graduated from Imperial College London with a BSc (Hons) First Class in 1995. Following service in the Singapore Armed Forces under a merit scholarship, from which he retired in 2003, he pursued PhD studies at the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland under the supervision of Paul Dyson. He then completed postdoctoral research at the Massachusetts Institute of Technology (MIT) in the laboratory of Stephen Lippard, focusing on the effects of Pt-DNA adducts on RNA transcription.
He joined NUS in 2009 as an Assistant Professor in the Department of Chemistry and was promoted to Associate Professor with tenure in 2015. His research centers on bioinorganic chemistry, including the development of therapeutic metallopharmaceuticals and techniques to investigate interactions of transition metal complexes with biomolecules. He has authored over 100 research articles, five reviews, and book chapters. Professor Ang serves as Vice Dean (Special Duties) and Associate Provost for NUS Multidisciplinary and Interdisciplinary Masters’ Programmes. He has been a member of the AsBIC Steering Committee since 2016 and chaired the 9th Asian Biological Inorganic Chemistry Conference.
Professional Email: null
NUS researchers uncover PTP1B as key target enhancing immunogenic cell death in cancer immunotherapy, per landmark JACS study. Explore implications for Singapore's oncology future.
NUS scientists uncover PTP1B as a critical switch for immunogenic cell death, enhancing cancer immunotherapy efficacy in colorectal models. Explore implications for Singapore's biomedical hub.
NUS scientists discover PTP1B protein as key target enhancing immunogenic cell death, supercharging cancer immunotherapy for better outcomes in colorectal and other cancers.
NUS researchers uncover PTP1B's role in immunogenic cell death, paving the way for advanced cancer immunotherapy targeting colorectal tumors.